Key result
Thrombopoietin receptor agonists linked to increased portal vein thrombosis risk in liver disease.
Key points are not available for this paper at this time.
TPO-RAs may elevate PVT risk in liver disease; leaves open causal confirmation and practice change.
* The first two authors contributed equally to this work. Online Supplementary Material (PDF)
No takes yet. Share an insight, caveat, or question.
Fan et al. (2015) studied this question. Thrombopoietin receptor agonists significantly increase the risk of portal vein thrombosis in patients with liver diseases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: